ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Aarey Drugs schedules a 14 November 2026 board meeting to approve unaudited half-year results. Trading window stays closed until 48 hours after results.
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulations.
Aarey Drugs approved allotment of 1,150,000 equity shares from warrant conversion at ₹47.85 each, receiving ₹5.50 Crore. Issued capital rises to 31,874,303 shares.
Promoter and promoter group of Aarey Drugs & Pharmaceuticals Ltd acquired 23.70 lakh shares following the conversion of warrants. The acquisition increased their stake by 4.81%.
Aarey Drugs allotted equity shares to promoters following the conversion of 23,40,000 warrants. This capital structure change increases the promoters' equity stake in the company.
Aarey Drugs & Pharmaceuticals Ltd. held its 36th Annual General Meeting on September 30, 2026, to conduct business including financial statement adoption and director re-appointment.
Aarey Drugs & Pharmaceuticals Ltd approved the allotment of 11,50,000 equity shares following the conversion of warrants. The allotment aggregate value is Rs. 7.34 Crore.
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern. This is a routine regulatory compliance disclosure regarding the company's equity distribution.
Aarey Drugs approved the Board Report and called its 36th Annual General Meeting to be held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹44.6 Cr (-56.4% YoY) and net profit of ₹1 Cr (-28.6% YoY) for Q1 FY27.
Aarey Drugs & Pharmaceuticals will hold a board meeting on August 14, 2026, to consider and approve the standalone unaudited financial results for the June 2026 quarter.
Aarey Drugs allotted 25.20 lakh equity shares upon conversion of warrants, raising Rs. 12.06 Crore. This issuance changes the company's paid-up equity capital.
The company has filed its quarterly shareholding pattern for the period ending June 30, 2026, as per regulatory requirements.
Aarey Drugs & Pharmaceuticals filed its Annual Secretarial Compliance Report for FY 2025-26. The report details regulatory compliance status and observations from the practicing company secretary.
Aarey Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹189.5 Cr (+75.3% YoY) and net profit of ₹1.6 Cr (+220.0% YoY) for Q4 FY26.
Aarey Drugs & Pharmaceuticals approved audited standalone financial results for FY26. The board also recorded a statement of no deviation in the utilization of preferential issue funds.
Aarey Drugs & Pharmaceuticals postponed its May 29 board meeting to May 30, 2026. The meeting will consider audited FY2026 financial results.
Aarey Drugs & Pharmaceuticals scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The trading window remains closed for designated persons.